FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3191264141> ?p ?o ?g. }

• W3191264141 endingPage "1218" @default.
• W3191264141 startingPage "1218" @default.
• W3191264141 abstract "Introduction: Luteolin (LUT) is natural flavonoid with multiple therapeutic potentials and is explored for transdermal delivery using a nanocarrier system. LUT loaded cationic nanoemulsions (CNE1–CNE9) using bergamot oil (BO) were developed, optimized, and characterized in terms of in vitro and ex vivo parameters for improved permeation. Materials and methods: The solubility study of LUT was carried out in selected excipients, namely BO, cremophor EL (CEL as surfactant), labrasol (LAB), and oleylamine (OA as cationic charge inducer). Formulations were characterized with globular size, polydispersity index (PDI), zeta potential, pH, and thermodynamic stability studies. The optimized formulation (CNE4) was selected for comparative investigations (% transmittance as %T, morphology, chemical compatibility, drug content, in vitro % drug release, ex vivo skin permeation, and drug deposition, DD) against ANE4 (anionic nanoemulsion for comparison) and drug suspension (DS). Results: Formulations such as CNE1–CNE9 and ANE4 (except CNE6 and CNE8) were found to be stable. The optimized CNE4 based on the lowest value of globular size (112 nm), minimum PDI (0.15), and optimum zeta potential (+26 mV) was selected for comparative assessment against ANE4 and DS. The %T values of CNE1–CNE9 were found to be ˃95% and CEL content slightly improved the %T value. The spherical CNE4 was compatible with excipients and showed % total drug content in the range of 97.9–99.7%. In vitro drug release values from CNE4 and ANE4 were significantly higher than DS. Moreover, permeation flux (138.82 ± 8.4 µg/cm2·h), enhancement ratio (8.23), and DD (10.98%) were remarkably higher than DS. Thus, ex vivo parameters were relatively high as compared to DS which may be attributed to nanonization, surfactant-mediated reversible changes in skin lipid matrix, and electrostatic interaction of nanoglobules with the cellular surface. Conclusion: Transdermal delivery of LUT can be a suitable alternative to oral drug delivery for augmented skin permeation and drug deposition." @default.
• W3191264141 created "2021-08-16" @default.
• W3191264141 creator A5003677451 @default.
• W3191264141 creator A5028029863 @default.
• W3191264141 creator A5048842637 @default.
• W3191264141 creator A5052758141 @default.
• W3191264141 creator A5065081772 @default.
• W3191264141 date "2021-08-07" @default.
• W3191264141 modified "2023-10-16" @default.
• W3191264141 title "Development and Evaluations of Transdermally Delivered Luteolin Loaded Cationic Nanoemulsion: In Vitro and Ex Vivo Evaluations" @default.
• W3191264141 cites W1967117653 @default.
• W3191264141 cites W1967296561 @default.
• W3191264141 cites W1968357749 @default.
• W3191264141 cites W1987615675 @default.
• W3191264141 cites W1990408513 @default.
• W3191264141 cites W1997951838 @default.
• W3191264141 cites W2009910338 @default.
• W3191264141 cites W2015313803 @default.
• W3191264141 cites W2018049003 @default.
• W3191264141 cites W2023965363 @default.
• W3191264141 cites W2025786477 @default.
• W3191264141 cites W2039576398 @default.
• W3191264141 cites W2041261502 @default.
• W3191264141 cites W2045356456 @default.
• W3191264141 cites W2048435858 @default.
• W3191264141 cites W2055368553 @default.
• W3191264141 cites W2061068952 @default.
• W3191264141 cites W2062655528 @default.
• W3191264141 cites W2066981744 @default.
• W3191264141 cites W2073401195 @default.
• W3191264141 cites W2078585577 @default.
• W3191264141 cites W2080222197 @default.
• W3191264141 cites W2082547599 @default.
• W3191264141 cites W2084977717 @default.
• W3191264141 cites W2088904910 @default.
• W3191264141 cites W2122216380 @default.
• W3191264141 cites W2154862932 @default.
• W3191264141 cites W2166547808 @default.
• W3191264141 cites W2213190405 @default.
• W3191264141 cites W2346899756 @default.
• W3191264141 cites W2410401733 @default.
• W3191264141 cites W2523515200 @default.
• W3191264141 cites W2564838688 @default.
• W3191264141 cites W2605160214 @default.
• W3191264141 cites W2697871094 @default.
• W3191264141 cites W2757037296 @default.
• W3191264141 cites W2768732619 @default.
• W3191264141 cites W2796068094 @default.
• W3191264141 cites W2800910258 @default.
• W3191264141 cites W2913289861 @default.
• W3191264141 cites W2988876016 @default.
• W3191264141 cites W3005931177 @default.
• W3191264141 cites W3010986703 @default.
• W3191264141 cites W3037606111 @default.
• W3191264141 cites W3088824125 @default.
• W3191264141 doi "https://doi.org/10.3390/pharmaceutics13081218" @default.
• W3191264141 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8398932" @default.
• W3191264141 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34452179" @default.
• W3191264141 hasPublicationYear "2021" @default.
• W3191264141 type Work @default.
• W3191264141 sameAs 3191264141 @default.
• W3191264141 citedByCount "18" @default.
• W3191264141 countsByYear W31912641412021 @default.
• W3191264141 countsByYear W31912641412022 @default.
• W3191264141 countsByYear W31912641412023 @default.
• W3191264141 crossrefType "journal-article" @default.
• W3191264141 hasAuthorship W3191264141A5003677451 @default.
• W3191264141 hasAuthorship W3191264141A5028029863 @default.
• W3191264141 hasAuthorship W3191264141A5048842637 @default.
• W3191264141 hasAuthorship W3191264141A5052758141 @default.
• W3191264141 hasAuthorship W3191264141A5065081772 @default.
• W3191264141 hasBestOaLocation W31912641411 @default.
• W3191264141 hasConcept C11432220 @default.
• W3191264141 hasConcept C155574463 @default.
• W3191264141 hasConcept C155672457 @default.
• W3191264141 hasConcept C171250308 @default.
• W3191264141 hasConcept C178790620 @default.
• W3191264141 hasConcept C18150654 @default.
• W3191264141 hasConcept C185592680 @default.
• W3191264141 hasConcept C192562407 @default.
• W3191264141 hasConcept C202751555 @default.
• W3191264141 hasConcept C205679159 @default.
• W3191264141 hasConcept C26291073 @default.
• W3191264141 hasConcept C2779820397 @default.
• W3191264141 hasConcept C41625074 @default.
• W3191264141 hasConcept C43617362 @default.
• W3191264141 hasConcept C50670333 @default.
• W3191264141 hasConcept C55493867 @default.
• W3191264141 hasConcept C71924100 @default.
• W3191264141 hasConcept C86181022 @default.
• W3191264141 hasConcept C98274493 @default.
• W3191264141 hasConceptScore W3191264141C11432220 @default.
• W3191264141 hasConceptScore W3191264141C155574463 @default.
• W3191264141 hasConceptScore W3191264141C155672457 @default.
• W3191264141 hasConceptScore W3191264141C171250308 @default.
• W3191264141 hasConceptScore W3191264141C178790620 @default.
• W3191264141 hasConceptScore W3191264141C18150654 @default.
• W3191264141 hasConceptScore W3191264141C185592680 @default.

• next